GlassScriptPhysician profile
Muhammad Afzal
NPI 1689600553
$72,219.68
in general payments reported to CMS, 2019-2025
17 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $18K · 2021: $5,485 · 2022: $7,158 · 2023: $15K · 2024: $2,920 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $1,281 · Food and Beverage: $907 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,377.75 |
| Travel and Lodging | $1,281.04 |
| Food and Beverage | $906.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $58,956.68 | 2019-2024 | Yupelri, Yupelri |
| Glaxosmithkline, LLC. | $12,198.75 | 2019-2021 | |
| Allergan, INC. | $205.24 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $118.25 | 2019-2023 | |
| Abbott Laboratories | $115.38 | 2019 | |
| Abbvie INC. | $113.63 | 2021-2025 | Avycaz |
| Biotronik INC. | $102.51 | 2025 | Amvia Edge |
| Astellas Pharma US INC | $99.00 | 2025 | |
| Inari Medical, INC. | $85.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $55.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.92 | 2019 | |
| Gilead Sciences, INC. | $32.69 | 2020 | |
| Merck Sharp & Dohme LLC | $28.71 | 2019 | |
| Shire North American Group INC | $27.41 | 2019 | |
| Grifols USA, LLC | $15.74 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $15.22 | 2020 | |
| United Therapeutics Corporation | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.